Literature DB >> 21339216

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

D E Furst1, E C Keystone, J Braun, F C Breedveld, G R Burmester, F De Benedetti, T Dörner, P Emery, R Fleischmann, A Gibofsky, J R Kalden, A Kavanaugh, B Kirkham, P Mease, J Sieper, N G Singer, J S Smolen, P L C M Van Riel, M H Weisman, K Winthrop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21339216     DOI： 10.1136/ard.2010.146852

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  19 in total

1.  Therapy: Off-label biologics use and infection risk-the great unknown.

Authors:  Kevin L Winthrop; Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2011-10-11       Impact factor: 20.543

2.  Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.

Authors:  Tatiana Cobo-Ibáñez; Miguel Ángel Descalzo; Estibaliz Loza-Santamaría; Loreto Carmona; Santiago Muñoz-Fernández
Journal:  Rheumatol Int       Date:  2014-01-11       Impact factor: 2.631

3.  Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.

Authors:  Stanley B Cohen; Joel M Kremer; Kimberly J Dandreo; George W Reed; Robert Magner; Ying Shan; Shelly Kafka; Raphael J DeHoratius; Lorie Ellis; Dennis Parenti
Journal:  Clin Rheumatol       Date:  2019-05-02       Impact factor: 2.980

4.  [Spondyloarthritides].

Authors:  J Braun; M Rudwaleit; J Sieper
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

5.  The use of biologic DMARDs identifies rheumatoid arthritis patients with more optimistic expectations of total knee arthroplasty.

Authors:  Susan M Goodman; Lisa A Mandl; Mark Figgie; Beverly K Johnson; Michael Alexiades; Hassan Ghomrawi
Journal:  HSS J       Date:  2014-02-19

6.  LLLT for the management of patients with ankylosing spondylitis.

Authors:  D Stasinopoulos; K Papadopoulos; D Lamnisos; A Stergioulas
Journal:  Lasers Med Sci       Date:  2016-01-21       Impact factor: 3.161

7.  B lymphocyte-typing for prediction of clinical response to rituximab.

Authors:  Hans-Peter Brezinschek; Franz Rainer; Kerstin Brickmann; Winfried B Graninger
Journal:  Arthritis Res Ther       Date:  2012-07-06       Impact factor: 5.156

8.  Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.

Authors:  Atsushi Ogata; Toru Hirano; Yoshihiro Hishitani; Toshio Tanaka
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2012-03-05

9.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

10.  Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.

Authors:  Machaon Bonafede; Barbara H Johnson; Kathleen M Fox; Crystal Watson; Shravanthi R Gandra
Journal:  J Dermatolog Treat       Date:  2013-05-21       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.